Novartis is discontinuing the development of pelacarsen for atherosclerotic cardiovascular disease due to its failure to meet primary endpoints in a Phase 3 trial. This decision, while impacting a specific drug program, signals a setback in Novartis's cardiovascular pipeline and could affect future revenue projections for this therapeutic area.
Novartis has announced the discontinuation of pelacarsen for atherosclerotic cardiovascular disease after the drug failed to meet its primary endpoints in the Phase 3 Lp(a)HORIZON trial. This is a significant setback for Novartis's cardiovascular pipeline, as pelacarsen was a late-stage asset. For Ionis Pharmaceuticals, the original discoverer, this represents a lost opportunity for potential milestone payments and royalties. While Novartis will continue to study the therapy for calcific aortic valve stenosis, the primary indication's failure could lead to a reassessment of the company's R&D strategy and potentially impact short-term investor sentiment due to the pipeline reduction. Traders should consider the implications for both NVS's future revenue streams and IONS's partnership prospects.